News
$Roivant Sciences(ROIV.US$ The Swiss pharmaceutical giant said Monday that it will pay $7.1 billion upfront and make a near-term milestone payment of $150 million to gain rights in the US and Japan to develop and market the drug known as RVT-3101.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
